# Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT02470585** · PHASE3 · TERMINATED · sponsor: **AbbVie** · enrollment: 1140 (actual)

## Conditions studied

- Ovarian Cancer
- Ovarian Neoplasm

## Interventions

- **DRUG:** Veliparib
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **OTHER:** Placebo to Veliparib

## Key facts

- **NCT ID:** NCT02470585
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-14
- **Primary completion:** 2019-05-03
- **Final completion:** 2023-10-05
- **Target enrollment:** 1140 (ACTUAL)
- **Why stopped:** Business decision not related to patient safety
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02470585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02470585, "Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02470585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*